Shionogi will buy Austin-based IntraBio for $2bn upfront, adding the approved rare-disease drug AQNEURSA to its growing US portfolio.
The Japanese drugmaker’s US subsidiary, Shionogi Inc., will acquire all outstanding shares of IntraBio. Once the deal closes, IntraBio will become a wholly owned subsidiary.
The deal at a glance
- Buyer: Shionogi Inc., the New Jersey-based US subsidiary of Shionogi
- Target: IntraBio Inc., Austin, Texas, founded in 2015
- Price: $2bn upfront to IntraBio’s shareholders
- Expected closing: November to December 2026, subject to competition and regulatory clearances
What Shionogi is buying
IntraBio develops and commercialises drugs for rare neurodegenerative and genetic neurological diseases. Its approved product, AQNEURSA (levacetylleucine), is approved in the US and EU for the neurological symptoms of Niemann-Pick disease type C.
The US Food and Drug Administration also approved AQNEURSA in September 2026 for ataxia in patients with Ataxia-Telangiectasia. The European Medicines Agency is reviewing it for the same use. IntraBio’s clinical programmes also include Pompe disease, Fragile X syndrome and Jordan’s syndrome.
Why it matters
- Commercial, not just pipeline. Shionogi is buying an approved product with a recent label expansion, which lowers the risk compared with buying early-stage assets.
- Japanese pharma looking west. The deal adds to a trend of Japanese drugmakers building their US presence through acquisitions.
- Rare disease remains a priority. Small patient groups, specialised distribution and premium pricing keep rare disease attractive for mid-sized pharma groups.
What it means for the supply chain
Rare disease medicines often move through specialty pharmacies and limited distribution networks, with close patient support. Ownership changes can bring changes to distribution partners, contract manufacturers and packaging suppliers as products are integrated into the buyer’s systems. Partners of IntraBio should watch for integration plans after closing.
The bottom line
Shionogi’s $2bn deal gives it an approved rare-disease product with growing indications. Expect integration news once the deal closes later this year.
Frequently Asked Questions
How much is Shionogi paying for IntraBio? $2bn in upfront cash to IntraBio’s shareholders.
What is AQNEURSA? AQNEURSA (levacetylleucine) is approved in the US and EU for neurological symptoms of Niemann-Pick disease type C. The FDA also approved it in September 2026 for ataxia in Ataxia-Telangiectasia.
When will the deal close? Shionogi expects it to close between November and December 2026, subject to clearances.
Where is IntraBio based? Austin, Texas.
Sources
| Source | Used for |
|---|---|
| Shionogi company announcement | Deal value, structure, product details and closing timeline |
| Lawrence, Evans & Co. healthcare deals digest | Deal summary |
| BioSpace | Deal coverage |
Additional Resources
| Resource | What you’ll find |
|---|---|
| Shionogi investor relations | Company strategy and announcements |
| US Food and Drug Administration (FDA) | Drug approval information |
| European Medicines Agency (EMA) | EU product assessments and reviews |
| National Organization for Rare Disorders (NORD) | Information on rare diseases, including Niemann-Pick disease type C |
Data note: AQNEURSA sales figures were not disclosed in the announcement and are not included.